Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: stroke + helps + 0.29  Related to the article below (Last Update: 8/5/2008)

DRIVETRAIN: 3.6-liter, 345-hp, 288-lb-ft H6; rwd, six-speed manual
AutoWeek - Jul 22, 2008
The new Carrera shares its predecessor's 0.29 coefficient of drag, despite a new front bumper with larger intakes and larger, dual-strut side mirrors. ...
Ten US Crews Race For Medals at 2008 FISA World Rowing Senior and ...
row2k.com, NJ - Jul 25, 2008
missed a spot in the final by just 0.29 seconds, finishing fourth in the first semifinal. The US was in second place at the 1500-meter mark, with Ukraine ...
Specific Lipids Supply Critical Negative Spontaneous Curvature-An ...
RedOrbit, TX - Jul 25, 2008
After CHOL depletion using a standardized treatment with 2 mM mbetaed (25,29), the specific curvature contributed by CHOL was -1.51 +- 0.29 amol ...
Source: Google News

Stroke in Devon: knowledge was good, but action was poor -
C Carroll, J Hobart, C Fox, L Teare, J Gibson - British Medical Journal, 2004 - jnnp.bmj.com
... 36.7) v 35.5% (16.8); 2 = 1.13, df = 1, p = 0.29). ... Medical help was sought by the
patient in 15 ... patients recognised they were having a stroke, illness delay was ...

Search -
TIA Dutch - Stroke - Am Heart Assoc
... 72, 0.35 (0.13?0.54), 188, 0.34 (0.22?0.45), 307, 0.29 (0.19?0.39), ... Stroke Home |
Subscriptions | Archives | Feedback | Authors | Help | AHA Journals ...

Search -
C Infarction, U Stroke, A Stroke - Stroke - Am Heart Assoc
... 1.37), 33 (14?52), 1.00 (0.62?1.62), 6 (0?17), 0.29 (0.12?.71 ... Stroke Home |
Subscriptions | Archives | Feedback | Authors | Help | AHA Journals ...

Prevention of stroke and dementia with statins effects beyond lipid lowering -
CJ Vaughan - The American Journal of Cardiology, 2003 - Elsevier
... This finding helps negate prior concerns that ... rat brain after experimentally induced
stroke and contributes ... receiving statin therapy was 0.29 (95% confidence ...

Participation after stroke compared to normal aging -
J Desrosiers, D Bourbonnais, L Noreau, A Rochette, … - Journal of Rehabilitation Medicine, 2005 - informaworld.com
... score 5.5 (1.8) 7.9 (0.7) 0.71 (0.23)*** 0.29 (0.22?0.36) ... aging and not entirely
to the stroke itself ... It helps to focus interventions on activities and roles ...

search for?
GS Session - Stroke - Am Heart Assoc
... 2, 0.38, 0.55, 0.29. SEV1, 1, 0.48, 0.48, 0.51. ... Return to article. Stroke Home |
Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home ...

Search
DW Recall, M Dispatch - Stroke - Am Heart Assoc
... narrowing, Present, 1300, 6.68, 0.03, 0.40, 46.1, 0.25, 0.49, 34.3, 0.29, 0.82. ... Stroke
Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals ...

… After First-Ever Stroke Predictors for Death, Dependency, and Recurrent Stroke Within the First … -
P Appelros, I Nydevik, M Viitanen - Stroke, 2003 - Am Heart Assoc
... of BI, 0.03 (95% CI, 0.003 to 0.09); and UND, 0.29 (95% CI ... Half of the patients
(n=13) did not seek medical help for their recurrent stroke, which was ...

… and Variability in the Interpretation of Early CT Changes in Stroke Patients Qualifying for … -
JC Grotta, D Chiu, M Lu, S Patel, SR Levine, BC … - Stroke, 1999 - Am Heart Assoc
... and the -value was only 0.39 (0.29, 0.49) (fair ... notably from the European Cooperative
Acute Stroke Trial (ECASS ... 33% of the MCA territory might help identify the ...

Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39) Evaluation of Acceptability, Reliability, and … -
K Hilari, S Byng, DL Lamping, SC Smith - Stroke, 2003 - Am Heart Assoc
... who were better/same, worse, or a lot worse than before the stroke (F (2 ... support
for convergent (r=0.44 to 0.59) and discriminant (r=0.26 to 0.29) validity of ...

Source: Google Scholar

"Preconditioning" Helps Protect Brain's Blood Vessels From Stroke - Therapeutic Potential Of Harnessing Tissue's Own Defenses
Challenging brain tissue with a small noxious stimulus beforehand gives it a resilience that can lessen damage to blood vessels during a stroke, report researchers at Weill Cornell Medical College in New York City.

"This preconditioning works along the theory of 'what doesn't kill me makes me stronger,'" explains senior researcher Dr. Costantino Iadecola, the George C. Cotzias distinguished professor of neurology and neuroscience and Director of Neurobiology at Weill Cornell, and attending neurologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

"We already knew that preconditioning helps minimize damage to heart tissue -- it's a strategy cardiologists routinely use today. And we know it can help protect brain cells -- neurons -- against stroke damage," Dr. Iadecola says. "Now, besides illuminating mechanisms involved in this process, our new study in mice demonstrates that preconditioning also shields the brain's blood vessels from stroke injury," he explains.
"The hope is that by studying this natural means of self-defense, we might develop potent pharmaceutical means of either preventing stroke or minimizing stroke damage," he says.

The findings appear as a special highlighted paper in the Journal of Neuroscience.

According to the National Stroke Association, stroke is the third leading killer of Americans and the number one cause of adult disability. And yet scientists have still not developed a truly effective means of treating these attacks.

"We knew that preconditioning -- giving the brain a slight noxious stimulus beforehand -- can strengthen brain cells against damage from a larger insult later on. This phenomenon occurs naturally in the human brain," explains lead researcher Dr. Alexander Kunz of the University of Dresden, Germany. Dr. Kunz worked on the study while at Weill Cornell.

But exactly how does preconditioning work, and can it come to the aid of the brain's vasculature, as well?

Based on their prior work, the researchers knew that the protective effect of preconditioning relies on a ubiquitous chemical in the blood called nitric oxide (NO). Injuries to tissues -- such as the ischemia that occurs in stroke -- activate certain enzymes that produce NO. This process also produces destructive, oxidative byproducts called free radicals.

According to the new study, NO combines with these free radicals to produce low levels of another molecule, called peroxynitrite.

"At higher levels, peroxynitrite is a very dangerous chemical for tissues," Dr. Iadecola explains. "But we discovered that at these lower concentrations, it's actually beneficial -- helping to preserve the function of blood vessels in the brain whenever a more toxic event occurs."

Normal mice given an inflammatory toxin called lipopolysaccharide (LPS) 24 hours before an induced stroke -- the preconditioning method used in this study -- had a 68 percent reduction in stroke intensity, the researchers found.

Preconditioning also boosted blood flow in areas of the brain unaffected by the stroke by 114 percent. However, mice that were genetically engineered so that they could not produce NO gained no such advantage from preconditioning. This suggests that NO and its chemical offspring, peroxynitrite, are essential to this protective process.

"Our study also demonstrates that preconditioning makes blood vessels more resilient against the damage caused by cerebral ischemia, just as it does for neurons," Dr. Iadecola notes. "After preconditioning, the vessels of the brain are impervious to the effects of the stroke and continue to function at a nearly normal level. That's something no one had shown before."

He stressed that it's far too dangerous to give patients peroxynitrite, so the goal here is to figure out how low concentrations of the chemical work their protective magic.
"What cell signaling mechanisms does it activate, for example? If we could find that out, we might be able to create a pharmaceutical mimic that could protect stroke patients," Dr. Iadecola says.

"The real novelty here is that we are looking for a stroke treatment that simply replicates strategies the brain is already using to protect itself," the researcher says. "There's a large population out there at high risk for stroke, and we believe this approach could really help them. It might even help minimize brain tissue damage should any stroke occur."

This work was supported by the U.S. National Institutes of Health and the Deutsche Forschungsgemeinschaft.

Co-researchers include Dr. Laibaik Park, Dr. Josef Anrather, Dr. Ping Zhou, Takato Abe and Eduardo Gallo -- all of the Division of Neurobiology at Weill Cornell Medical College.

Weill Cornell Medical College

Weill Cornell Medical College -- Cornell University's Medical School located in New York City -- is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Weill Cornell, which is a principal academic affiliate of NewYork-Presbyterian Hospital, offers an innovative curriculum that integrates the teaching of basic and clinical sciences, problem-based learning, office-based preceptorships, and primary care and doctoring courses. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research in such areas as stem cells, genetics and gene therapy, geriatrics, neuroscience, structural biology, cardiovascular medicine, AIDS, obesity, cancer, psychiatry and public health -- and continue to delve ever deeper into the molecular basis of disease in an effort to unlock the mysteries behind the human body and the malfunctions that result in serious medical disorders. The Medical College -- in its commitment to global health and education -- has a strong presence in such places as Qatar, Tanzania, Haiti, Brazil, Salzburg, and Turkey. With the historic Weill Cornell Medical College in Qatar, the Medical School is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- from the development of the Pap test for cervical cancer to the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the world's first clinical trial for gene therapy for Parkinson's disease, and, most recently, the first indication of bone marrow's critical role in tumor growth.

http://www.med.cornell.edu
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.